2022 AHA/ACC/HFSA guideline for the management of heart failure: a report of the American College of Cardiology/American Heart Association Joint Committee on …
Abstract Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Ischemia and no obstructive coronary arteries (INOCA): a narrative review
Myocardial ischemia with no obstructive coronary arteries (INOCA) is a chronic coronary
syndrome condition that is increasingly being recognized as a substantial contributor to …
syndrome condition that is increasingly being recognized as a substantial contributor to …
[HTML][HTML] 2022 Guidelines of the Taiwan Society of Cardiology and the Taiwan Hypertension Society for the management of hypertension
Hypertension is the most important modifiable cause of cardiovascular (CV) disease and all-
cause mortality worldwide. Despite the positive correlations between blood pressure (BP) …
cause mortality worldwide. Despite the positive correlations between blood pressure (BP) …
How Carvedilol activates β2-adrenoceptors
T Benkel, M Zimmermann, J Zeiner, S Bravo… - Nature …, 2022 - nature.com
Carvedilol is among the most effective β-blockers for improving survival after myocardial
infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are …
infarction. Yet the mechanisms by which carvedilol achieves this superior clinical profile are …
2022 ACC/AHA/HFSA guideline for the management of heart failure
ABSTRACT Aim The “2022 AHA/ACC/HFSA Guideline for the Management of Heart Failure”
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
replaces the “2013 ACCF/AHA Guideline for the Management of Heart Failure” and the …
Medicare coverage and out-of-pocket costs of quadruple drug therapy for heart failure
Background Beta-blockers, angiotensin receptor-neprilysin inhibitor (ARNI),
mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors …
mineralocorticoid receptor antagonists, and sodium-glucose cotransporter-2 inhibitors …
Treatment and prescribing trends of antihypertensive drugs in 2.7 million UK primary care patients over 31 years: a population-based cohort study
Objectives To describe the prescribing trends of antihypertensive drugs in primary care
patients and assess the trajectory of antihypertensive drug prescriptions, from first-line to …
patients and assess the trajectory of antihypertensive drug prescriptions, from first-line to …
Impact of socioeconomic status on mortality and readmission in patients with heart failure with reduced ejection fraction: the ARIC study
Background Low socioeconomic status (SES) is associated with a higher risk of heart failure
(HF). The contribution of individual and neighborhood SES to the prognosis and quality of …
(HF). The contribution of individual and neighborhood SES to the prognosis and quality of …
Rationale and design of the pragmatic clinical trial tREatment with Beta-blockers after myOcardial infarction withOut reduced ejection fracTion (REBOOT)
X Rossello, S Raposeiras-Roubin… - European Heart …, 2022 - academic.oup.com
Aims There is a lack of evidence regarding the benefits of β-blocker treatment after
invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection …
invasively managed acute myocardial infarction (MI) without reduced left ventricular ejection …
Contemporary drug treatment of advanced heart failure with reduced ejection fraction
JKK Vishram-Nielsen, D Tomasoni, F Gustafsson… - Drugs, 2022 - Springer
The introduction of multiple new pharmacological agents over the past three decades in the
field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of …
field of heart failure with reduced ejection fraction (HFrEF) has led to reduced rates of …